-
公开(公告)号：US11857629B2
公开(公告)日：2024-01-02
申请号：US17366256
申请日：2021-07-02
IPC分类号： A61K47/02 , A61K31/5517 , A61K47/32 , A61K9/20
CPC分类号： A61K47/02 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/5517 , A61K47/32
摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
-
2.发明申请公开(公告)号：US20180326065A1
公开(公告)日：2018-11-15
申请号：US16041331
申请日：2018-07-20
IPC分类号： A61K47/02 , A61K9/20 , A61K47/32 , A61K31/5517
摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
-
公开(公告)号：US20170143635A1
公开(公告)日：2017-05-25
申请号：US15426296
申请日：2017-02-07
IPC分类号： A61K9/20 , A61K31/485 , A61K31/4458 , A61K31/137 , A61K31/5517
CPC分类号： A61K47/38 , A61K9/1635 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2072 , A61K31/137 , A61K31/4458 , A61K31/485 , A61K31/5517 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/32
摘要： Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.
-
4.发明授权Methods and compositions for self-regulated release of active pharmaceutical ingredient 有权用于自我调节释放活性药物成分的方法和组合物公开(公告)号：US09101636B2
公开(公告)日：2015-08-11
申请号：US14091817
申请日：2013-11-27
IPC分类号： A61K9/20 , A61K31/5517
CPC分类号： A61K47/02 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/5517 , A61K47/32
摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
摘要翻译： 包含药物活性成分的滥用威慑药物组合物; 酸溶性成分; 和缓冲成分; 其中当组合物摄取超过预期剂量时，酸溶性成分和缓冲成分阻止活性药物成分的释放。
-
公开(公告)号：US20140336213A1
公开(公告)日：2014-11-13
申请号：US14339143
申请日：2014-07-23
发明人： Vijai Kumar , David Dixon , Divya Tewari , Dilip B. Wadgaonkar
IPC分类号： A61K31/485 , A61K9/20
CPC分类号： A61K31/485 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2095 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K47/32 , A61K47/34 , A61K47/38
摘要： This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.
摘要翻译： 本发明涉及治疗性药物组合物，其包含：包含阿片样物质的混合物; 该聚环氧乙烷的量为组合物的约3至约40重量％; 崩解剂 和表面活性剂; 其中所述崩解剂以足以使所述药物组合物呈现立即释放曲线的量存在。
-
公开(公告)号：US08637540B2
公开(公告)日：2014-01-28
申请号：US13926206
申请日：2013-06-25
发明人： Vijai Kumar , David Dixon , Divya Tewari , Dilip B. Wadgaonkar
IPC分类号： A61K9/00 , A61K9/20 , A61K31/00 , A61K31/485
CPC分类号： A61K31/485 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2095 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K47/32 , A61K47/34 , A61K47/38
摘要： This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
摘要翻译： 本发明涉及一种阿片类镇痛药的滥用威慑剂型，其中将镇痛有效量的阿片类止痛剂与聚合物组合以形成基质。
-
7.发明公开公开(公告)号：US20240108726A1
公开(公告)日：2024-04-04
申请号：US18539830
申请日：2023-12-14
IPC分类号： A61K47/02 , A61K9/20 , A61K31/5517 , A61K47/32
CPC分类号： A61K47/02 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/5517 , A61K47/32
摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
-
8.发明公开公开(公告)号：US20230330044A1
公开(公告)日：2023-10-19
申请号：US18213524
申请日：2023-06-23
发明人： Ronald L. Leech, JR.
CPC分类号： A61K31/137 , A61K9/2059 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32 , A61K47/38
摘要： Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
-
公开(公告)号：US11723885B2
公开(公告)日：2023-08-15
申请号：US17521581
申请日：2021-11-08
发明人： Ronald L. Leech, Jr.
CPC分类号： A61K31/137 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32 , A61K47/38
摘要： Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
-
10.发明申请公开(公告)号：US20170239354A1
公开(公告)日：2017-08-24
申请号：US15588982
申请日：2017-05-08
IPC分类号： A61K47/02 , A61K47/32 , A61K31/5517
CPC分类号： A61K47/02 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/5517 , A61K47/32
摘要： An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.035 秒)
